[何清湖; 朱闽] School of Integrated Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;[朱闽; 戴芳; 徐楠] Department of Andrology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi 530011, China;[赵自垒; 荀建宁] Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi 530001, China;[荀建宁] Department of Andrology, Yucheng People's Hospital, Yucheng, Henan 476300, China
Evidence-based complementary and alternative medicine : eCAM,2018年2018:5290514 ISSN：1741-427X
Yan, Miao;Fan, Xin-Rong
[He, Qing-Hu; Nie, Yu-Song; Zhang, Ling; Fan, Xin-Rong; Xie, Hui] College of Integrated Traditional Chinese and Western Medicine, Hunan University of Chinese Medicine, Changsha, Hunan Province 410208, China;[Yan, Miao; Zhang, Ling] Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province 410011, China;[Zhang, Ling; Fan, Xin-Rong] Institute of Basic Theory for Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;[Zhang, Min] First Clinical Medical College, Shanxi University of Chinese Medicine, Xianyang, Shanxi Province 712000, China
[Yan, Miao] Cent S Univ, Xiangya Hosp 2, Dept Pharm, Changsha 410011, Hunan, Peoples R China.;[Fan, Xin-Rong] China Acad Chinese Med Sci, Inst BasicTheory Chinese Med, Beijing 100700, Peoples R China.;[Fan, Xin-Rong] Hunan Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Changsha 410208, Hunan, Peoples R China.
Benign prostatic hyperplasia (BPH) is a common disease in the current ageing male population. This research aims to study the effects of Kelong-Capsules (KLC) on testosterone-induced BPH. Thirty rats were randomly divided into normal group, model group, and three treatment groups. Three treatment groups were given KLC (3.6 g/kg), KLC (7.2 g/kg), and finasteride (0.9 mg/kg), respectively, for 28 days after establishing the animal model. The BPH rat models were evaluated by Traditional Chinese Medicine (TCM) symptoms and prostate index (PI). Results indicated that three treatment groups all alleviated the pathological changes of prostate and kidney at different levels. Compared with the model group, the PI of the groups treated with KLC (7.2 g/kg) and finasteride decreased significantly. The expressions of NF-E2 related factor 2 (Nrf-2) and quinine oxidoreductase (NQO1) in the group treated with KLC (3.6 g/kg) increased markedly (p < 0.01). The cyclooxygenase-2 (COX-2) protein expression of the group treated with KLC (7.2 g/kg) was increased (p < 0.01). In conclusion, KLC could obviously inhibit the growth of prostate, and KLC (3.6 g/kg) could promote the expressions of Nrf2 and NQO1.